#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
A recent systematic review examined preclinical and clinical evidence for cannabidiol (CBD) as a potential antipsychotic agent in schizophrenia, highlighting its distinct pharmacological profile compared to THC. The review emphasizes CBD’s interaction with serotonin signaling pathways and other neurobiological mechanisms that may contribute to antipsychotic effects without the psychotomimetic properties associated with THC. While preclinical data and early clinical observations show promise, the authors note that robust randomized controlled trials comparing CBD to standard antipsychotics are limited, and questions remain regarding optimal dosing, duration of treatment, and long-term efficacy and safety. Current evidence suggests CBD may warrant investigation as an adjunctive or alternative treatment for patients who experience intolerable side effects from conventional antipsychotic medications or demonstrate treatment resistance. Clinicians considering CBD for psychotic symptoms should recognize that existing evidence is preliminary and should counsel patients that established antipsychotics remain the standard of care pending completion of higher-quality clinical trials. Patients interested in CBD for schizophrenia should discuss this option only within the context of comprehensive psychiatric care and in settings where adequate monitoring for symptom response and adverse effects can be maintained.
🧠 While preclinical and early clinical evidence suggests cannabidiol (CBD) may modulate psychotic symptoms through serotonergic and other neurobiological pathways, current evidence remains limited by small sample sizes, short treatment durations, and heterogeneous outcome measures across studies. The mechanistic plausibility is intriguing, but clinicians should note that most patients with schizophrenia benefit from established antipsychotics with decades of efficacy data, and CBD has not demonstrated superiority to first-line treatments in head-to-head trials. Important confounders include variable CBD formulations and purity in commercially available products, potential drug-drug interactions with psychiatric medications, and the risk of cannabis use itself as a psychosis trigger in vulnerable populations. At present, CBD cannot replace standard antipsychotic therapy, though it may warrant consideration as an adjunctive option in select patients with partial response to conventional treatment, provided
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
